Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Blood (2025) 146 (25): 3086–3097.

https://doi.org/10.1182/blood.2025030177

Published: 2025

Includes: Supplemental data

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci

Blood (2025) 146 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2025-3583

Published: 2025

Journal Articles

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

Alberto Guijosa, Nickolas Tsakmaklis, Margaret Kobs, Nina Budano, Julia Nguyen, Alexandra Eurell, Maria Luisa Guerrera, Gottfried von Keudell, Andrew Branagan, Zachary Hunter, Steven Treon, Shayna Sarosiek, Jorge Castillo

Blood (2025) 146 (Supplement 1): 3577.

https://doi.org/10.1182/blood-2025-3577

Published: 2025

Journal Articles

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.

Shirong Liu, Xia Liu, Amanda Kofides, John Hatcher, Nickolas Tsakmaklis, Abigail Peachey, Dominic Pizzarella, Alberto Guijosa, Jinhua Wang, Maria Luisa Guerrera, Christopher Patterson, Zachary Hunter, Shayna Sarosiek, Jorge Castillo, Sara Buhrlage, Steven Treon

Blood (2025) 146 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2025-2171

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Blood (2025) 146 (Supplement 1): 225.

https://doi.org/10.1182/blood-2025-225

Published: 2025

Journal Articles

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Nickolas Tsakmaklis, Alberto Guijosa, Andres Ramirez, Amanda Kofides, Abigail Peachey, Xia Liu, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 224.

https://doi.org/10.1182/blood-2025-224

Published: 2025

Journal Articles

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Shayna Sarosiek, Mary Kwok, Prashant Kapoor, Hannah Chory, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Alberto Guijosa, Nickolas Tsakmaklis, Zachary Hunter, Andrew Branagan, Steven Treon, Jorge Castillo

Blood (2025) 146 (Supplement 1): 581.

https://doi.org/10.1182/blood-2025-581

Published: 2025

Journal Articles

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

Xia Liu, Shirong Liu, Amanda Kofides, Dominic Pizzarella, Jinhua Wang, Sara Buhrlage, Nickolas Tsakmaklis, Abigail Peachey, Alberto Guijosa, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, John Hatcher, Steven Treon

Blood (2025) 146 (Supplement 1): 5324.

https://doi.org/10.1182/blood-2025-5324

Published: 2025

Journal Articles

Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies

Blood (2025) 146 (Supplement 1): 2332.

https://doi.org/10.1182/blood-2025-2332

Published: 2025

Journal Articles

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Zachary Hunter, Amanda Kofides, Abigail Peachey, Nickolas Tsakmaklis, Maria Luisa Guerrera, Xia Liu, Shirong Liu, Hao Sun, Alberto Guijosa, John Hatcher, Dominic Pizzarella, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2025-3544

Published: 2025

Journal Articles

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Blood (2025) 146 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2025-3543

Published: 2025

Journal Articles

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Nicholas Paciaroni, Nina Budano, Julia Nguyen, Kirsten Meid, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Zachary Hunter, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 5392.

https://doi.org/10.1182/blood-2025-5392

Published: 2025

Journal Articles

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

Jorge Castillo, Andrew Branagan, Gottfried von Keudell, Alberto Guijosa, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Nickolas Tsakmaklis, Zachary Hunter, Steven Treon, Shayna Sarosiek

Blood (2025) 146 (Supplement 1): 1794.

https://doi.org/10.1182/blood-2025-1794

Published: 2025

Journal Articles

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Blood (2025) 146 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2025-5731

Published: 2025

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Blood (2025) 146 (Supplement 1): 5490.

https://doi.org/10.1182/blood-2025-5490

Published: 2025

Journal Articles

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Dominic Pizzarella, Amanda Kofides, Xia Liu, John Hatcher, Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Jinhua Wang, Maria Luisa Guerrera, Christopher Patterson, Zachary Hunter, Hao Sun, Shayna Sarosiek, Jorge Castillo, Sara Buhrlage, Sirano Dhe-Paganon, Steven Treon, Shirong Liu

Blood (2025) 146 (Supplement 1): 7453.

https://doi.org/10.1182/blood-2025-7453

Published: 2025

Journal Articles

Spatial profiling of the bone marrow microenvironment in patients with IgM gammopathies reveals a T cell–Enriched tumor niche associated with asymptomatic waldenstrom macroglobulinemia progression

David Cordas Dos Santos, Kane Foster, Daniel Heilpern-Mallory, Sophia Schroeder, Minhua Su, Vidhi Patel, Catherine Tobia, Mohammed Rahman, Jacqueline Perry, Daniel Zangrando, Nina Lane, Yoshinobu Konishi, Steven Treon, Gad Getz, Irene Ghobrial

Blood (2025) 146 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2025-3559

Published: 2025

Journal Articles

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe-Paganon, John Hatcher, Andres Ramirez, Dominic Pizzarella, Amanda Kofides, Abigail Peachey, Shirong Liu, Hao Sun, Xia Liu, Maria Luisa Guerrera, Andrew Branagan, Gottfried von Keudell, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2025-3611

Published: 2025

Journal Articles

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Abdul Hamid Bazarbachi, MD, Herve Avet-Loiseau, Zachary R Hunter, PhD, Raphael Szalat, Anil Aktas-Samur, PhD, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Mariateresa Fulciniti, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Steven Treon, Mohamad Mohty, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138951

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Spatial profiling of the bone marrow microenvironment in patients with IgM gammopathies reveals a T cell–Enriched tumor niche associated with asymptomatic waldenstrom macroglobulinemia progression

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only